about
Current developments in pharmacological therapeutics for chronic constipationObesity: Current and potential pharmacotherapeutics and targets.AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel diseaseGroup 1B phospholipase A₂ inactivation suppresses atherosclerosis and metabolic diseases in LDL receptor-deficient mice.Gastrointestinal localization of metronidazole by a lactobacilli-inspired tetramic acid motif improves treatment outcomes in the hamster model of Clostridium difficile infection.Folate Receptor-Targeted Polymeric Micellar Nanocarriers for Delivery of Orlistat as a Repurposed Drug against Triple-Negative Breast CancerConvective washout reduces the antidiarrheal efficacy of enterocyte surface-targeted antisecretory drugsSevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease.The bile acid membrane receptor TGR5: a novel pharmacological target in metabolic, inflammatory and neoplastic disorders.Tenapanor hydrochloride for the treatment of constipation-predominant irritable bowel syndrome.Intestinal phospholipid and lysophospholipid metabolism in cardiometabolic disease.Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis.The importance of intake: a gut feeling.Cation Exchange Resins and colonic perforation. What surgeons need to know.Preclinical and Healthy Volunteer Studies of Potential Drug-Drug Interactions Between Tenapanor and Phosphate Binders.Comparative Pharmacokinetic Study for Linezolid and Two Novel Antibacterial Oxazolidinone Derivatives in Rabbits: Can Differences in the Pharmacokinetic Properties Explain the Discrepancies between Their In Vivo and In Vitro Antibacterial ActivitiesNew therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond.Pharmacodynamics, Safety, and Tolerability of the NHE3 Inhibitor Tenapanor: Two Trials in Healthy Volunteers.Development and Characterization of a Human and Mouse Intestinal Epithelial Cell Monolayer Platform.
P2860
Q27025474-35D9EF3D-4DCC-46C7-97E5-F11507A55F27Q30243992-9A51D923-1FC2-48DC-8BBA-90F775A79ED0Q30565359-DEC2D849-FDF9-4C6C-8AD7-407B8E6AB11DQ33683167-36434A45-D9DA-4E27-8583-1D4F3EF8DAA6Q36367042-D47CAB08-DA57-4F5F-ADF1-C4C80C29BF94Q36563827-594AB591-92E0-435A-921A-D533DA5602DBQ36568476-35DB12AA-944E-4D2D-AA3F-D74A4242CEEBQ37567574-CF8C82D2-847F-492B-B207-8FB11F769566Q38115636-68A61871-1659-431C-9A3E-33B663795840Q38525007-81D523B2-89DB-4B11-AE43-E327F29DF769Q38903367-00FA7ED8-4845-4C10-9E1B-92F36EE4E553Q40050616-16E7977C-BD55-4B92-9211-706EB7BCBE28Q41848858-9571C7E8-9821-4409-8B68-773EFC4BEF19Q42006308-89F47059-BE50-4F73-91A3-E80FA2889A45Q42025679-1F3E9418-701F-4213-82D5-6AC2ACFCABD5Q42366838-B84147F3-733D-4DC0-86FF-70E02A0F9EFDQ42695148-7A22911B-4C93-4207-9B27-2E8AEC98D537Q48179198-276CEC9A-248F-4BD6-A9B6-2B0B26E3A0B5Q49476554-774CCA21-C22B-41A9-8600-74F4AF4A5FCE
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Non-systemic drugs: a critical review
@ast
Non-systemic drugs: a critical review
@en
Non-systemic drugs: a critical review
@nl
type
label
Non-systemic drugs: a critical review
@ast
Non-systemic drugs: a critical review
@en
Non-systemic drugs: a critical review
@nl
prefLabel
Non-systemic drugs: a critical review
@ast
Non-systemic drugs: a critical review
@en
Non-systemic drugs: a critical review
@nl
P2860
P921
P1476
Non-systemic drugs: a critical review
@en
P2093
P2860
P304
P356
10.2174/138161212799504858
P407
P577
2012-01-01T00:00:00Z